BIOC insider filings

BIOCEPT INC — 30 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2022-11-18. Screen BIOC transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for BIOC between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — BIOCEPT INC

FiledFormInsiderReported transactionsSource
2022-11-184DAO-HADDOCK QUYEN THI — DirectorGrant/award (A): 10,000 (derivative) @ $0EDGAR
2022-09-084Chandler Marsha Alpert — DirectorGrant/award (A): 10,000 (derivative) @ $0EDGAR
2022-09-084Rubinstein Linda M — DirectorGrant/award (A): 10,000 (derivative) @ $0EDGAR
2022-09-084Gerhardt Bruce — DirectorGrant/award (A): 10,000 (derivative) @ $0EDGAR
2022-09-084Wilson Margaret Faye — DirectorGrant/award (A): 10,000 (derivative) @ $0EDGAR
2022-09-084ROYSTON IVOR — DirectorGrant/award (A): 10,000 (derivative) @ $0EDGAR
2022-04-044Taylor Darrell — See remarksGrant/award (A): 15,450 (derivative) @ $0EDGAR
2022-04-044Marchand Philippe — Chief Operations OfficerGrant/award (A): 150,000 (derivative) @ $0EDGAR
2022-03-164Taylor Darrell — Sr. V.P., General CounselGrant/award (A): 134,550 (derivative) @ $0EDGAR
2022-03-024Riccitelli Samuel D — Interim President and CEO, DirectorGrant/award (A): 250,000 (derivative) @ $0EDGAR
2022-03-024Morales Antonino — Interim CFO, DirectorGrant/award (A): 150,000 (derivative) @ $0EDGAR
2021-12-104HALE DAVID F — DirectorSale (S): 363 @ $4.06 · Sale (S): 11 @ $4.07 · Sale (S): 71 @ $4.07EDGAR
2021-09-024Nall Michael W. — CEO & President, DirectorGrant/award (A): 100,000 (derivative) @ $0 · Grant/award (A): 80,000 (derivative) @ $0EDGAR
2021-09-024TERRY MICHAEL J — Sr VP of Business DevelopmentGrant/award (A): 35,000 (derivative) @ $0EDGAR
2021-09-024DUGAN MICHAEL C — Chief Med Off & Med. DirectorGrant/award (A): 150,000 (derivative) @ $0EDGAR
2021-09-024Kennedy Timothy — CFO, COO & SecretaryGrant/award (A): 100,000 (derivative) @ $0EDGAR
2021-07-204Wilson Margaret Faye — DirectorGrant/award (A): 10,000 (derivative) @ $0EDGAR
2021-07-204Gerhardt Bruce — DirectorGrant/award (A): 10,000 (derivative) @ $0EDGAR
2021-07-204Chandler Marsha Alpert — DirectorGrant/award (A): 10,000 (derivative) @ $0EDGAR
2021-07-204Riccitelli Samuel D — DirectorGrant/award (A): 10,000 (derivative) @ $0EDGAR
2021-07-204Rubinstein Linda M — DirectorGrant/award (A): 10,000 (derivative) @ $0EDGAR
2021-07-204Morales Antonino — DirectorGrant/award (A): 10,000 (derivative) @ $0EDGAR
2021-07-204ROYSTON IVOR — DirectorGrant/award (A): 10,000 (derivative) @ $0EDGAR
2021-07-204HALE DAVID F — DirectorGrant/award (A): 10,000 (derivative) @ $0EDGAR
2020-10-224Riccitelli Samuel D — DirectorGrant/award (A): 10,000 (derivative) @ $0EDGAR
2020-10-054TERRY MICHAEL J — Sr VP Comm. OperationsGrant/award (A): 48,300 (derivative) @ $0EDGAR
2020-10-054Kennedy Timothy — CFO, Sr V.P. Operations & Sec.Grant/award (A): 138,000 (derivative) @ $0EDGAR
2020-10-054DUGAN MICHAEL C — Chief Med Off & Med. DirectorGrant/award (A): 69,000 (derivative) @ $0EDGAR
2020-10-054Nall Michael W. — CEO & President, DirectorGrant/award (A): 241,500 (derivative) @ $0EDGAR
2020-09-014DUGAN MICHAEL C — Chief Med Off & Med. DirectorGrant/award (A): 54,900 (derivative) @ $0EDGAR

Recent 8-K events — BIOCEPT INC

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2023-10-208-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingEDGAR
2023-10-168-K1.03 — Bankruptcy or Receivership
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
EDGAR
2023-08-228-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2023-06-218-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2023-05-168-K3.03 — Material Modification to Rights of Security Holders
9.01 — Financial Statements and Exhibits
EDGAR
2023-05-158-K2.02 — Results of Operations and Financial Condition
3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
5.07 — Submission of Matters to a Vote of Security Holders
9.01 — Financial Statements and Exhibits
EDGAR
2023-04-178-K4.02 — Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim ReviewEDGAR
2023-04-178-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2023-04-108-K1.01 — Entry into a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
3.03 — Material Modification to Rights of Security Holders
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits
EDGAR
2023-03-208-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=BIOC returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs